Key Statistics
- Another milestone for Numinus. Numinus announced today that it has been given the regulatory green light from Health Canada to test the safety and efficacy of whole psilocybe cubensis tea. Psilocybe cubensis is the most well- known type of hundreds of hallucinogenic mushroom species that contain psilocybin and psilocin because this species grows easily. Back in October 2022, Numinus unveiled a first-of-its-kind psilocybe tea bag (EnfiniTea) it had developed for the upcoming Phase I trial to make it more palatable for use by certain populations, such as people receiving palliative care for serious illnesses who might find ingesting whole mushrooms or pills unappealing. Numinus has developed the processes and procedures to deliver 25 mg per dose and the use of its validated strains of psilocybe cubensis.
- An important experiential training opportunity for therapists. Not only will this be the first-of-its-kind opportunity to test the safety and efficacy of whole psilocybe mushrooms in a clinical setting, but just as critical, it is a unique opportunity to provide experiential training to practitioners who will be responsible for delivering important mental health treatments such as psilocybin to patients in the future.
- Enrollment for trial will begin shortly. Numinus will begin enrolling volunteers for the Phase I Open-Label Single-Arm Study to Evaluate Psilocybin Experiential Training in the next several weeks. Numinus will select volunteers from those practitioners who are trained or are currently training to provide psilocybin-assisted therapy through Numinus' Practitioner Training Program or other approved training programs. The trial will initially be conducted in Numinus’ clinic in Vancouver, with initial results from the study expected to be published in the second half of 2023.
- Scaling up and training of practitioners are key to Numinus’ strategy. In our fireside chat with Numinus CEO Payton Nyquvest on December 8, 2022, he emphasized how core the training of practitioners is to Numinus’ strategy of becoming a leading provider of much-needed mental health services. Given the anticipated growth in demand for psychedelic-assisted therapies, a key plank of Numinus’ strategy has been scaling up of its practitioner base and engagement in a very robust amount of training for those higher-margin services. The upcoming psilocybe cubensis clinical trial, along with Numinus’ other training programs, go very much together with that strategy.
Another milestone for Numinus. Numinus announced today that it has been given the regulatory green light from Health Canada to test the safety and efficacy of whole psilocybe cubensis tea. Psilocybe cubensis is the most well- known type of hundreds of hallucinogenic mushroom species that contain psilocybin and psilocin because this species grows easily. Back in October 2022, Numinus unveiled a first-of-its-kind psilocybe tea bag (EnfiniTea) it had developed for the upcoming Phase I trial to make it more palatable for use by certain populations, such as people receiving palliative care for serious illnesses who might find ingesting whole mushrooms or pills unappealing. Numinus has developed the processes and procedures to deliver 25 mg per dose and the use of its validated strains of psilocybe cubensis.
Water Tower Research (“WTR”) is a professional publisher of investment research reports on public companies and, to a lesser extent, private firms (“the Companies”). WTR provides investor-focused content and digital distribution strategies designed to help companies communicate with investors.
WTR is not a registered investment adviser or a broker/dealer nor does WTR provide investment banking services. WTR operates as an exempt investment adviser under the so called “publishers’ exemption” from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940. WTR does not provide investment ratings / recommendations or price targets on the companies it reports on. Readers are advised that the research reports are published and provided solely for informational purposes and should not be construed as an offer to sell or the solicitation of an offer to buy securities or the rendering of investment advice. The information p...